Free tool
FAERS Monitor: Kimmtrak
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761228 or its brand name (Kimmtrak, Tebentafusp-Tebn). Reports on generic versions are filed under their own applications.
Reports
602
Serious
457
76% of reports
Hospitalization
201
Death reported
107
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome118
- pyrexia107
- disease progression73
- hypotension70
- rash69
- malignant neoplasm progression61
- chills59
- product dose omission issue56
- pruritus44
- nausea40
- vomiting36
- death32
- fatigue24
- hypoxia22
- diarrhoea20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2022 | 100 |
| 2023 | 104 |
| 2024 | 134 |
| 2025 | 139 |
| 2026 | 123 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,557 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytokine release syndromeSignal | 118 | 206.7 | 175.8 | 23,837 |
| hypoxiaSignal | 22 | 21.8 | 14.5 | 417 |
| disease progressionSignal | 73 | 21.6 | 17.4 | 1,418 |
| malignant neoplasm progressionSignal | 61 | 20.8 | 16.4 | 1,136 |
| chillsSignal | 59 | 17.6 | 13.8 | 911 |
| hypotensionSignal | 70 | 12.2 | 9.8 | 715 |
| pyrexiaSignal | 107 | 10.8 | 9.1 | 958 |
| product dose omission issueSignal | 56 | 6.7 | 5.2 | 267 |
| rashSignal | 69 | 5.5 | 4.4 | 257 |
| pruritusSignal | 44 | 4.0 | 3.0 | 98 |
| vomitingSignal | 36 | 2.7 | 1.9 | 37 |
| nausea | 40 | 1.8 | 1.3 | 13 |
| death | 32 | 1.3 | 0.9 | 2 |
| diarrhoea | 20 | 1.1 | 0.7 | 0 |
| fatigue | 24 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.